A judge has rejected Samsung Bioepis’ bid to discover research and development documents from Pfizer as it seeks to invalidate the drug giant’s patent for its blockbuster autoimmune drug Enbrel, agreeing with Pfizer that it may be “no more than an exercise in fishing”.
Drug giant Pfizer has blasted Samsung Bioepis’ âfishing expeditionâ in its suit alleging infringement of the patent for its blockbuster arthritis drug Enbrel, telling the court the Korean biotech should not be allowed to dig for new grounds of invalidity. Â
Graphics design platform Canva has overcome opposition to it being granted further time to apply to patent an invention for generating websites, after IP Australia found its US patent attorneys made an “error or omission” by failing to track expiration dates for registering the patent.
Gaming giant Aristocrat Technologies has lost its legal challenge to a decision that rejected a patent for its popular Lightning Link electronic poker machine, after six High Court Justices were equally split on whether it could be patented.
Explosives manufacturer Orica is closer to taking Dyno Nobel to court for allegedly infringing three of its explosives patents, filing proceedings to get more information about its rival’s CyberDet wireless detonator device.
Two of the world’s largest manufacturers of explosives have taken their fight over three patents for a detonation device to the Federal Court.
Pharmaceutical giant Pfizer has fired off a lawsuit against four drug companies for allegedly infringing one of its patents for biologic Enbrel by selling a biosimilar of the blockbuster arthritis drug in Australia.
National fitness chain F45 has appealed a court decision revoking two of its patents for a computer-run trainer workout system, arguing its system constituted a technological innovation in the field of fitness studio franchising which rival Body Fit has profited from.
A judge has revoked two patents held by national fitness chain F45 for a computer-run trainer workout system.
Five years into a preliminary discovery application for a potential patent infringement lawsuit over a biosimilar of its Enbrel medication, Pfizer has partially succeeded in obtaining further documents from Samsung Bioepis.